Please assess the completion status of the following clinical trial:

Trial Title: Warfarin Initiation in Mechanical Mitral Valve Replacement Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New mechanical mitral valve prostheses patients who will receive anticoagulation with warfarin with the use of enoxaparen as a bridging agent.~Exclusion Criteria:~* Pregnant or lactating women~* Renal disorder (GFR = 45\< mL/min) or patients on renal dialysis~* Hepatic disorder (Child Pugh class B or C)~* Clinically significant active bleeding.~* Recurrent DVT or PE.~* Baseline INR \>1.2~* Asian ancestry~* Cancer~* Impaired nutritional status~* Alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): a group of 25 patients received 5mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period.
- Group II (Type: EXPERIMENTAL): a group of 25 patients received 3mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).